Study reveals how SGLT2 inhibitors improve failing heart function by activating PANK1
核心洞察
Researchers at the University of Pennsylvania discovered that SGLT2 inhibitors (搜索) directly activate the enzyme PANK1 (搜索) in heart cells, boosting coenzyme A production and improving energy metabolism.
The study, published in Science, potentially solves a longstanding gap in understanding why these diabetes (搜索)-derived drugs reduce hospitalizations and deaths in heart failure (搜索) patients.
Activating PANK1 (搜索) alone reproduced many of the drugs' benefits, while blocking the pathway largely eliminated them, supporting PANK1 as a major driver of the therapeutic effect.
Researchers have discovered that SGLT2 inhibitors (搜索), a class of drugs originally developed to treat diabetes (搜索) and now widely used for heart failure (搜索), work by activating a key enzyme that helps heart cells produce and use energy more efficiently. The study, published today in Science, potentially solves a longstanding gap in knowledge about these drugs and opens the door to potential new treatments for heart failure.
The study, led by researchers in the Perelman School of Medicine at the University of Pennsylvania, found that SGLT2 inhibitors (搜索) directly activate an enzyme called PANK1 (搜索) in heart cells. This activation boosts production of coenzyme A (CoA), a molecule essential for converting nutrients into energy. Researchers found that increasing CoA production improved the ability of human heart cells to contract and relax, two critical functions that are impaired in heart failure (搜索).
"Our findings suggest these drugs are helping the failing heart restore its energy-producing capacity," said senior author Zoltan Arany, MD, PhD, the Samuel Bellet Professor of Cardiology and chair of Physiology at Penn Medicine. "We identified PANK1 (搜索) as a direct target of these medications and found that activating this pathway makes heart cells work better. This may explain many of the remarkable benefits patients experience with these drugs."
Figuring out why it works
For years, physicians have known that SGLT2 inhibitors (搜索) significantly reduce hospitalizations and deaths among heart failure (搜索) patients, but have struggled to explain exactly why, because the drugs were designed to target the SGLT2 protein, which is found in the kidneys, not the heart.
Using human heart tissue from transplant recipients and donors, the researchers found that SGLT2 inhibitors (搜索) increased the heart's ability to use multiple fuel sources, including sugars, fats, amino acids, and ketones. The drugs also increased levels of CoA, which plays a central role in cellular energy production. To identify how that happened, the team traced the effect back to PANK1 (搜索), an enzyme that regulates the first and most important step in CoA production. The researchers demonstrated that the drugs physically bind to PANK1 and activate it.
"The evidence was especially compelling when we found that activating PANK1 (搜索) alone reproduced many of the benefits of the drugs, while blocking the pathway largely eliminated those benefits," said Nicholas Forelli, MD, an internal medicine resident in the Arany lab and co-author of the study. "We cannot completely rule out other contributing mechanisms, but the data strongly support PANK1 as a major driver."
The discovery may also help explain why SGLT2 inhibitors (搜索) often begin benefiting heart failure (搜索) patients within days of starting treatment.
Exciting possibilities ahead
Despite years of research into these medications, the role of PANK1 (搜索) had gone unnoticed. "Honestly, no one thought to look," Arany said. "Researchers knew these drugs were doing something important in the heart, but the target responsible for those effects had remained elusive."
The findings could have important implications for future drug development. While SGLT2 inhibitors (搜索) are highly effective, they can cause side effects such as urinary tract infections, dehydration, and, in rare cases, diabetic ketoacidosis. "One of the most exciting possibilities is developing drugs that directly target PANK1 (搜索)," Arany said. "That could allow us to capture the heart benefits while potentially avoiding some of the side effects associated with current therapies. We're actively working on that now."
The study was funded in part by the National Institutes of Health (HL152446, K08HL159311, T32HL0078, R01 HL149891, S10-OD018483), the NIH project ALS-ENABLE (P30 GM124169), the Johnson Research Foundation, the Sarnoff Foundation, the Leducq Foundation, and a DreamTeam grant from the Penn Cardiovascular Institute and the Children's Hospital of Philadelphia Frontier Program.